An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)

被引:27
作者
Corrales-Rodriguez, Luis [1 ,2 ]
Arrieta, Oscar [3 ,4 ]
Mas, Luis [5 ]
Baez-Saldana, Renata [6 ]
Castillo-Fernandez, Omar [7 ]
Blais, Normand [8 ]
Martin, Claudio [9 ]
Juarez, Melissa [1 ,2 ]
Khanna, Priyanka [2 ]
Ramos-Esquivel, Allan [1 ]
Bacon, Ludwing [10 ]
Rojas, Leonardo [11 ,12 ]
Wills, Beatriz [13 ]
Oblitas, George [14 ]
Angelina Perez, Maria [15 ]
Cuello, Mauricio [16 ]
Felipe Cardona, Andres [17 ,18 ,19 ]
机构
[1] Hosp San Juan Dios, Med Oncol, San Jose, Costa Rica
[2] Ctr Invest & Manejo Canc CIMCA, 275 Metros Oeste JPS, San Jose, Costa Rica
[3] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City, DF, Mexico
[4] Inst Nacl Cancerol INCan, Lab Personalized Med, Mexico City, DF, Mexico
[5] INEN, Clin Oncol Dept, Lima, Peru
[6] Inst Nacl Enfermedad Resp, Mexico City, DF, Mexico
[7] Inst Oncol Nacl Panama, Dept Oncol, Panama City, Panama
[8] Hop Notre Dame CHUM, Montreal, PQ, Canada
[9] Inst Fleming, Thorac Oncol Unit, Med Oncol Dept, Buenos Aires, DF, Argentina
[10] Hosp Roberto Calderon, Oncol Dept, Managua, Nicaragua
[11] Hosp San Ignacio, Ctr Javeriano Oncol, Clin Oncol Dept, Bogota, Colombia
[12] Pontificia Univ Javeriana, Internal Med Dept, Bogota, Colombia
[13] Johns Hopkins Univ, Internal Med Dept, Baltimore, MD USA
[14] Inst Oncol Luis Razetti, Caracas, Venezuela
[15] Unidad Oncol Venezuela, Caracas, Venezuela
[16] UdeLAR, Med Oncol Dept, Montevideo, Uruguay
[17] Clin Country, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia
[18] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia
[19] Univ El Bosque, Internal Med Dept, Fdn Santa Fe Bogota, Bogota, Colombia
关键词
NSCLC; Young; Adenocarcinoma; 40 years old; Age; Non-smokers; GROWTH-FACTOR RECEPTOR; EGFR-MUTATIONS; 1ST-LINE CRIZOTINIB; LATIN-AMERICA; WOOD-SMOKE; OPEN-LABEL; SURVIVAL; CHEMOTHERAPY; AGE; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2017.08.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies have documented and analyzed epidemiological characteristics of this population. Materials and methods: We performed an international epidemiological analysis of 389 young patients with NSCLC. Data was collected from centers participating in the Latin American Consortium for Lung Cancer Research (AduJov-CLICaP). Patients were identified and data was retrospectively collected from different Latin American countries and Canada (Argentina = 6, Canada = 19, Colombia = 29, Costa Rica = 9, Mexico = 219, Nicaragua = 2, Panama = 19, Peru = 76 and Venezuela = 10). The period of study was from 2012 to 2017. Inclusion criteria were: age 40 years or less and a histologically confirmed NSCLC. Clinical data was obtained, and EGFR mutation status and EML4-ALK translocation were collected. Results: NSCLC patients aged 40 years or less accounted for approximately 4% of the total NSCLC population. Female patients accounted for 54.5%, while median age was of 37 years. Adenocarcinoma accounted for 86.1% (n = 335/389), 72.5% (n = 282/389; unknown = 5) of patients were non-smokers, and 90.3% (n = 351/389) had stage IV disease. Site of metastasis was obtained from 260/351 (unknown = 91) stage IV patients (lung metastasis = 40.0%, CNS metastasis = 35.7%, and bone metastasis = 31.5%). OS for the total population was 17.3 months (95%CI = 13.9-20.7). OS for EGFRm(+) = 31.4 months (95%CI = 11.6-51.3), EGFRm(-) = 14.5 months (95%CI = 11.0-17.9) (p = 0.005). OS for alk(+) = 9.8 months (95%CI = 3.1-16.5) and alk(-) = 5.6months (95%CI = 3.9-7.3) (p = 0.315). Conclusions: Patients aged 40 years or less account for a small but important proportion of NSCLC cases. Younger patients may have different characteristics compared to the older population. EGFRm and EML4-alk translocation frequency is higher than that of the general population.
引用
收藏
页码:30 / 36
页数:7
相关论文
共 60 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], AM J CLIN ONCOL
[3]  
[Anonymous], N ENGL J MED
[4]   REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL AMONG LOCALLY-ADVANCED/METASTATIC ALK plus NON-SMALL CELL LUNG CANCER PATIENTS IN LATIN AMERICA [J].
Arrieta, O. ;
Mascheroni, M. B. ;
Recondo, G. ;
Kaen, D. ;
Zhang, J. ;
Patel, D. ;
Swallow, E. ;
Balu, S. ;
Camacho, O. C. ;
Ratto, B. ;
Kageleiry, A. ;
Stein, K. ;
Degun, R. ;
Martin, C. .
VALUE IN HEALTH, 2015, 18 (07) :A817-A817
[5]  
Arrieta O., 2015, J THORAC ONCOL, V10, pS407
[6]  
Arrieta O., 2015, J THORAC ONCOL, pS696
[7]   Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox" [J].
Arrieta, Oscar ;
Ramirez-Tirado, Laura-Alejandra ;
Baez-Saldana, Renata ;
Pena-Curiel, Omar ;
Soca-Chafre, Giovanny ;
Macedo-Perez, Eleazar-Omar .
LUNG CANCER, 2015, 90 (02) :161-166
[8]   Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer [J].
Arrieta, Oscar ;
De la Torre-Vallejo, Martha ;
Lopez-Macias, Diego ;
Orta, David ;
Turcott, Jenny ;
Macedo-Perez, Eleazar-Omar ;
Sanchez-Lara, Karla ;
Ramirez-Tirado, Laura-Alejandra ;
Baracos, Vickie E. .
ONCOLOGIST, 2015, 20 (08) :967-974
[9]   Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) [J].
Arrieta, Oscar ;
Cardona, Andres F. ;
Martin, Claudio ;
Mas-Lopez, Luis ;
Corrales-Rodriguez, Luis ;
Bramuglia, Guillermo ;
Castillo-Fernandez, Omar ;
Meyerson, Matthew ;
Amieva-Rivera, Eduardo ;
Delia Campos-Parra, Alma ;
Carranza, Hernn ;
Carlos Gomez de la Torre, Juan ;
Powazniak, Yanina ;
Aldaco-Sarvide, Fernando ;
Vargas, Carlos ;
Trigo, Mariana ;
Magallanes-Maciel, Manuel ;
Otero, Jorge ;
Sanchez-Reyes, Roberto ;
Cuello, Mauricio .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :838-843
[10]   The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer [J].
Arrieta, Oscar ;
Felipe Cardona, Andres ;
Corrales, Luis ;
Delia Campos-Parra, Alma ;
Sanchez-Reyes, Roberto ;
Amieva-Rivera, Eduardo ;
Rodriguez, July ;
Vargas, Carlos ;
Carranza, Hernan ;
Otero, Jorge ;
Karachaliou, Nikki ;
Astudillo, Horacio ;
Rosell, Rafael .
LUNG CANCER, 2015, 87 (02) :169-175